

ABSTRACT OF THE DISCLOSURE

The present invention provides a CD40-targeted gene delivery system and a CD40-targeted recombinant adenoviral vector
5 for genetic manipulation of dendritic cells and B cells. Also provided are methods of using this enhanced gene delivery to immune system cells and therefore, enhancing dendritic cell-based immunotherapy.

002190-2E2T6560